We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BioResearch

DNA-barcode Labeled Nanoparticles Trace Drug Susceptibility

Novel DNA-barcoded nanoparticles loaded with anti-cancer drugs were used to screen for susceptibility at the cellular level as a first step in the development of personalized cancer therapy. More...
23 Nov 2016
Image: Photomicrographs of fibroblasts from patients with Huntington\'s disease marked with fluorescence. Top row: the cells have accumulated mutant RNA. Bottom row: the cells no longer show blocked RNA accumulations (Photo courtesy of the Center for Genomic Regulation).

Blocking Mutant RNA Cures Huntington's Disease in Mouse Model

Researchers seeking ways to treat Huntington's disease have suggested going after the messenger RNA that mediates between the mutant gene that causes the disease and the toxic protein that causes the neurological damage that characterizes it. More...
23 Nov 2016
Image: A micrograph of prostate adenocarcinoma, acinar type, the most common type of prostate cancer (Photo courtesy of Wikimedia Commons).

Mitochondrial Protein Linked to Development of Prostate Cancer

Results obtained from experiments with genetically engineered mouse models revealed a direct link between the mitochondrial chaperone protein, TRAP1 (TNF receptor associated protein 1) and the development of prostate cancer. More...
23 Nov 2016
Image: Two adjacent sections of a mouse breast tumor. Tissue at left is stained so that normal blood vessels can be seen (black arrow). Extending from these vessels are blood filled channels (green arrows). On the right, the tissue is stained for a fluorescent protein expressed by the tumor cells. Here it is seen that blood-filled channels are actually formed by tumor cells in a process known as vascular mimicry (Photo courtesy of Cold Spring Harbor Laboratory).

Macrophages Form Vascular Mimicry Channels to Supply Growing Tumors

A potential new therapeutic approach to block cancer development is based on the finding that macrophages form primitive non-endothelial “vessels” or vascular mimicry channels that help supply growing tumors with oxygen and nutrients. More...
22 Nov 2016
Image: An artist\'s concept of a domain-swapped T-cell receptor (TCR) engaging a peptide presented by a tumor cell on a major histocompatibility complex (MHC) molecule. In TCR gene therapy, genes encoding a tumor-specific TCR are introduced to a patient\'s T-cells, retargeting them to attack cancer cells. Swapping the constant domains between the alpha and beta chains of the tumor-specific TCR prevents these chains from mispairing with the TCR chains resident to each T-cell, which can result in autoimmune disease (Photo courtesy of the California Institute of Technology).

Modified T-Cells Attack Tumors without Triggering Autoimmune Disease

A team of molecular immunologists has devised a method to direct T-cells to recognize and fight cancer cells without risk of the modified cells attacking normal tissues and thereby triggering autoimmune disease. More...
22 Nov 2016
Image: A digitally colorized transmission electron micrograph (TEM) of Zika virus. Virus particles, here colored red, are 40 nanometers in diameter, with an outer envelope, and an inner dense core (Photo courtesy of the CDC).

DNA-based Zika Vaccine Demonstrates Potential in Animal Models

A DNA-based vaccine has shown promise in protecting animal models against infection and brain damage caused by the Zika virus. More...
22 Nov 2016
Image: The NS1 monobody binds to H-RAS or K-RAS protein and blocks RAS function by disrupting the protein\'s ability to form active molecular pairs (Photo courtesy of Dr. John P. O\'Bryan, University of Chicago).

Experimental Monobody Drug Inhibits Most Mutated RAS Oncogenes

A novel monobody drug candidate was found to effectively block the action of most of the RAS family of proto-oncogenes, which are mutated in nearly 90% of pancreatic cancers and are also highly prevalent in colon cancer, lung cancer, and melanoma. More...
17 Nov 2016
Gold Member
Hematology Analyzer
Swelab Lumi
Automated Blood Typing System
IH-500 NEXT
New
Nuclear Matrix Protein 22 Test
NMP22 Test
New
Auto-Chemistry Analyzer
CS-1200


BioResearch brings the latest research news on the genome, proteome, metabolome, on drug discovery, and therapeutics. Biotech researchers, lab administrators, technologists, drug manufacturers, and suppliers can find the latest research news and information related to their fields of endeavor here.